Repligen Corporation (RGEN) Reached 52-Week High on Jun, 29 at $47.72

June 29, 2018 - By Alice Fox

Repligen Corporation (NASDAQ:RGEN) Corporate Logo

During 2018 Q1 the big money sentiment increased to 1.39. That’s change of 0.13, from 2017Q4’s 1.26. 13 investors sold all, 46 reduced holdings as Repligen Corporation ratio is positive. 63 increased positions while 19 funds bought positions. Funds hold 35.98 million shares thus 2.25% more from 2017Q4’s 35.19 million shares.
Aperio Group Limited Liability Co stated it has 35,583 shs or 0.01% of all its holdings. Ls Investment Advisors Lc invested 0.01% in Repligen Corporation (NASDAQ:RGEN). State Of Tennessee Treasury Department reported 0% stake. Palisade Cap Lc Nj has invested 0.93% in Repligen Corporation (NASDAQ:RGEN). Daiwa Group Incorporated accumulated 0% or 241 shs. 1,990 were reported by Zurcher Kantonalbank (Zurich Cantonalbank). Hightower Advsrs Limited Liability Com has 0.01% invested in Repligen Corporation (NASDAQ:RGEN) for 18,627 shs. Dekabank Deutsche Girozentrale stated it has 17,600 shs. Moreover, Ameritas Invest Partners Incorporated has 0.01% invested in Repligen Corporation (NASDAQ:RGEN). Falcon Point Cap Limited Liability Com reported 0.1% in Repligen Corporation (NASDAQ:RGEN). 3,582 were reported by Us Savings Bank De. Principal Financial Grp Incorporated owns 302,002 shs. 16,003 are owned by Voya Mngmt Llc. Proshare Advsrs Lc has 26,117 shs for 0.01% of their capital. Citigroup has invested 0% in Repligen Corporation (NASDAQ:RGEN).

Repligen Corporation registered $13.05 million net activity with 0 insider buys and 8 sales since January 22, 2018. Hunt Anthony sold $322,445 worth of Repligen Corporation (NASDAQ:RGEN) or 8,970 shs on Monday, January 22. $1.07M worth of Repligen Corporation (NASDAQ:RGEN) shs were sold by BARTHELEMY NICOLAS. 1,932 shs were sold by RYAN THOMAS F JR, worth $85,606 on Wednesday, June 6. Another trade for 20,000 shs valued at $835,936 was sold by DAWES KAREN A.

Repligen Corporation (NASDAQ:RGEN) hit $47.72 stock price also a yearly high. It was published on Jun, 29 according to Barchart.com. It has $2.09 billion MC. The valuation of NASDAQ:RGEN can change by $145.95M if our $51.06 price target is hit.

The stock increased 1.97% or $0.92 during the last trading session, reaching $47.72.Currently Repligen Corporation is uptrending after 11.84% change in last June 29, 2017. RGEN has 118,185 shares volume. RGEN underperformed by 0.73% the S&P500.

On August, 2 Repligen Corporation (NASDAQ:RGEN)’s earnings report is anticipated by WallStreet, as reported by RTT. This year’s earnings per share analyst estimate is anticipated to be $0.19. That is 5.00 % down compareed to $0.2 earnings per share for last year. If RGEN’s EPS is $0.19 the profit will hit $8.30M for 62.79 P/E. Analysts at Wall Street see Repligen Corporation’s 11.76 % EPS growth compared to $0.17 earnings per share for last quarter.

A couple more Repligen Corporation (NASDAQ:RGEN) news were posted by: Nasdaq.com which released on June 27, 2018 “Repligen Announces Agreement with Navigo Proteins for the Exclusive Co-Development of Next Generation Affinity …”, also Nasdaq.com on June 28, 2018 posted “Repligen Selects Purolite Life Sciences as Commercial Partner for New High Performance Ligand”, the next Globenewswire.com is “Report: Exploring Fundamental Drivers Behind Matthews International, Raytheon, JetBlue Airways, Repligen, Becton …” on June 11, 2018. Benzinga.com has article titled “Benzinga’s Daily Biotech Pulse: Pain Therapeutics Drops 70%, Neon To Begin Trading”.

Repligen Corporation, a bioprocessing company, focuses on the development, production, and commercialization of products used in the production of antibody therapeutics, recombinant proteins, and vaccines worldwide.The firm is worth $2.09 billion. It makes various forms of Protein A, a critical component used to purify antibody drugs.66.28 is the P/E ratio. The firm also supplies alternating tangential flow system filtration devices and protein cell culture supplements that are used in clinical and commercial stage manufacturing to enhance biologic drug yields.

Repligen Corporation (NASDAQ:RGEN) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.